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The went study. In this star of th . Journal, Prau ct ill
(1) use
e•d
ata from the Cardiac Arrhythmia Pilot Study
(CAPS) placebo group to evaluate spontaneous
variability
in
the frequency of ventricular premature depolanzatmns and
in the occurrence of nonsustained ventricular tach' .curdia in
the year after myocardial infarction . When applying the
CAPS findings, one should always recall that the CAT'S
patient sample was selected for time after myocardial intro-
tion, age . ventricular premature depolarization frequency
and left ventricular ejection fraction- The I1 patients in the
placebo group had frequent continuous 34 h recordings
during I year of follow-up- The variability in ventricular
premature depolarization frequency among recordings tins
substantial enough for nearly i0ff00 of the patients to satisfy
the CAPS criteria for antiarrhythmic eific icy at least once .
and lie- > 10% of them to exhibit an apparent proarrhythmic
effect la m10-fold increase in ventriculerpremature depolar-
izalion frequency) at least once by the end of dosing . Llcrc
inspection of the data indicates the futility of urine the
presence of nonsustained ventricular t'achycardia . a'osc
frequency event • tojudge antiarrhythmic efficacy or a proar-
rhythmic effect.
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.hug Ireatment . We hire discussed sources of
s .tri
:tClin insentricularpremature depolariiationfrequcnes
el505 For 1 n-1 : the hypothesis that the decrease in Lequeraa
betsceen the baseline and the first treatment evaluation Lane
1, suhstantully due to regression to the mean 'n a reasonable
ono . We compared ventricular premature depolarization
frcgrlen¢, in two 24 h counnuous FL(j recordings made
month, apa-t in the placebo group of the \lultisev er D It-
iazcT Po,t-infarction Trial and found trial the frequency of
vcnrncular prmamre depolarieations doubled in the bottom
quit
.,Le of the frequency distribution but halved Ir the top
quarrrk t tl
. Ihls marked and symmetuc change in sentne-
ulai t,remautre depolarization frcqucne3 is strong evidence
for regression to the mean and supports the hypothesis of
Prate et al . I I) .
hasstal studies 13 .41 in representative postinfarction pa-
beat ,ample, showed that tentocular pramatnrcdepolanza-
tton frequency increases from I cr' weeks alter she mfarc-
Iion to approximately 3 months and then fluctuates about a
	 • . ; ;:ble mean value .'rhis pattern as not evident in
the CAPS ample . which was limited to the upper quintile of
the ccmrisular premature depolarization frequency distribu-
tion. Pratt at al . I Il assert that the frequency of ventrcular
prem.eare depolarization decreased significantly (p - 0 .04)
from i to C months after the beginning of the trial . The
stgnilicancc of the decline may be overstated because of the
future n, adlu,t the significance level for the multiplicity of
tests thin Here performed t9 . When the Ronferroni adjust-
ment is applied i .e't
. the decline from 3 to IZ months become,,
of borderline significance best .
The decrease in veriricclar premature to-polarization
irequene •, during the I it' sack ofplaceho treatment might he
aerihuted to a puaceb . 'feet . However, we have examined
a number of samples am have not been able to demonstrate
.-
.ieMfi.,nl placebo e .Teet on the frequency of ventricular
n-rhn'thmia,
. Regression to the mean is a better explanation .
Prat et al . have the impression that the variability of
scnlrlcular premature depielanzallon frequency is higher in
the scar ;ruler myocardial infarction than at other times or in
g
: sups other than postinfarction patients . This hypothesis
his not been proved, but it is reasonable considering the
t o nt,ibdir y ol'the course of illness in the year after mvocardial
in arcti-,n . n period associated with especially high rates of
mertality . rcitfaretion and other events 161 .
rherapeulie implications . Pratt el al . (1) discuss how
variahdity in the rates of ventricular arrhythmias makes
intcrprelatinn of antiarrhythmic responses difficult after
my u,ard,d infarction . They suggest that longer recordings
before and after starting antiarrhythmic ding treatment
.Id improve the classification of responses as antiarrhyth-
mic or proirrhyfnmic . but they also point eel the logistic and
fiscal cnnslramts on such an approach . By restricting the
uoproach to a single 24 h electrocardiographic (ECG) record-
ing ref are treatment and a single recording after treatment .
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one could change the criteria for efficacy and proarrhythmia
so that there were fewer false positive results . However.
such changes would carry with them a substantial
price . The
price for a more stringent criterion for efficacy would be a
substantial increase in the prevalence of cardiac and noncar-
diac toxicity . assuming that failure to achieve
efficacy
would
result in an increased dose of the drug
. The therapeutic ratio
of antiarrhylhmic drugs with class 1 action is not high .
placing severe limits on 0cxiblity in dosing 11 really is not
practical to require 7115: to 80th arrhythmia suppression to
classify a respunse as dill iarrhythmic .
Using criteria similar to those of Pratt ec al . r i 1 in a large
placebo-treated group, we found a false positive proarrhylh-
min rate of aheul Se/ (3), This rate could he reduced by
changing the criteria but the price would
be an increase in
the false negative rule, that is. the rate of failure to detect
parietals whose arrhythmia
was . in
fact . aggravated by treat-
ment . In our view • this would be unacceptable .
In contrast to the difficulties in
evaluating
pulients, it is
easy to detect and quantify anliarrhythmic action by using
responses to a range of doses even in small groups of
patients . If a large study showed a positive correlation
between arrhythmia suppression and improved survival after
infarction, then despite regression to the mean . a 70th to 80`/
reduction would be a reesonable criterion of antiarrhythmic
action to use in individual patients receiving prophylactic
treatment
.
Conclusions. In tight of the difficulties discussed by Pratt
et al . (I ) . it is apparent that ventricular arrhythmias in the
year after myocardial infarction are better indicators of
mortality risk than of anliarrhythmic drug efficacy. They
resemble left ventricular ejection fraction and the signal-
averaged ECG in this respect . The Cardiac Arrhythmia
Suppression Trial ICASTI results also suggest that suppres-
sion
of ventricular arrhythmias after myocardial infarction
with encainide or flecainide selects a low risk group if
treatment is not continued after the initial titration for
arrhythmia suppression .
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Finally . it should he emphasized that CAST (7) and other
studies iS91 have shown that patients with ventricular
arrhythmias after myocardial infarction, but with no or only
minimal symptoms . should not he treated with any antiar-
rhythmic drag with class I action until one of these drugs is
showy to improve survival significantly . This recommenda-
tion acoids altogether the need to deal with the complex
issues with which the CAPS dale: on arrhythmia variability
confront us .
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